<DOC>
	<DOCNO>NCT00647348</DOCNO>
	<brief_summary>To determine whether simvastatin dose 80mg reduce rate whole brain atrophy , measure MRI , 2-year time-period compare placebo .</brief_summary>
	<brief_title>Investigation Simvastatin Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description>The study complete study data process review correlate .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Patients must confirm diagnosis multiple sclerosis randomisation enter secondary progressive stage . Steady progression rather relapse must major cause increase disability precede 2 year . Progression evident either increase least one point EDSS clinical documentation increase disability . EDSS 4.0 6.5 inclusive Women childbearing age require use appropriate method contraception avoid unlikely teratogenic effect simvastatin . Able give write informed consent 18 65 year Unable give inform consent Primary progressive MS Those experienced relapse treat steroid ( i.v . oral ) within 3 month screen visit . These patient may undergo screen visit 3 month window expire may include steroid treatment administer intervening period . Patient already take anticipate take statin . Any medication unfavourably interact statin : fibrates , nicotinic acid , cyclosporine , azole antifungal preparation , macrolideantibiotics , protease inhibitor , nefazodone , verapamil , amiodarone , large amount grapefruit juice alcohol abuse . The use immunosuppressant ( e.g . azathioprine , methotrexate , cyclosporine ) disease modify treatment ( avonex , rebif , betaferon , glatiramer ) within previous 6 month . The use mitoxantrone treat within last 12 month . If patient ever treat alemtuzumab . If screening level alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) creatine kinase ( CK ) three time upper limit normal patient exclude . Patient unable tolerate baseline scan scan adequate quality analysis ( e.g . much movement artefact ) . If female patient pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Secondary progressive Multiple Sclerosis</keyword>
	<keyword>Simvastatin</keyword>
	<keyword>MRI</keyword>
</DOC>